Future prospects of EGFR-TKIs and surgery for non-small-cell lung cancer

被引：0
作者：
Nagano, Tatsuya [1 ]
Tachihara, Motoko [1 ]
Tanaka, Yugo [2 ]
机构：
[1] Kobe Univ, Dept Internal Med, Div Resp Med, Grad Sch Med, Kobe, Hyogo, Japan
[2] Kobe Univ, Div Thorac Surg, Grad Sch Med, Kobe, Hyogo, Japan
来源：
JOURNAL OF THORACIC DISEASE | 2022年 / 14卷 / 04期
关键词：
OSIMERTINIB;
D O I：
10.21037/jtd-22-57
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：809 / 811
页数：3
相关论文
共 50 条
  • [41] Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with EGFR-mutated non-small-cell lung cancer: a retrospective, multicenter cohort study
    Tanaka, Ichidai
    Hori, Kazumi
    Koyama, Junji
    Gen, Soei
    Morise, Masahiro
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Ishii, Makoto
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [42] Exosomal long non-coding RNA SOX2 overlapping transcript enhances the resistance to EGFR-TKIs in non-small cell lung cancer cell line H1975
    Zhou, Dongbo
    Xia, Zhi
    Xie, Mingxuan
    Gao, Ying
    Yu, Qiao
    He, Baimei
    HUMAN CELL, 2021, 34 (05) : 1478 - 1489
  • [43] Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer?
    Kulkarni, Amit A.
    Naqash, Abdul Rafeh
    Puri, Sonam
    Dienstmann, Rodrigo
    JCO PRECISION ONCOLOGY, 2021, 5 : 408 - 414
  • [44] Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer
    Van Veggel, B.
    Van der Wekken, A.
    Hashemi, S.
    Cornelissen, R.
    Monkhorst, K.
    Heideman, D.
    Radonic, T.
    Schuuring, E.
    Smit, E.
    De Langen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S815 - S815
  • [45] The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study
    Hu, Jia
    Huang, Di
    Wang, Yanrong
    Li, Donghui
    Yang, Xuejiao
    Fu, Yan
    Du, Nan
    Zhao, Yan
    Li, Xiaosong
    Ma, Junxun
    Hu, Yi
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [46] EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations
    Kim, Edward S.
    Melosky, Barbara
    Park, Keunchil
    Yamamoto, Nobuyuki
    Yang, James C-H
    FUTURE ONCOLOGY, 2021, 17 (18) : 2395 - 2408
  • [47] Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives
    Rebuzzi, Sara Elena
    Alfieri, Roberta
    La Monica, Silvia
    Minari, Roberta
    Petronini, Pier Giorgio
    Tiseo, Marcello
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 146
  • [48] Perioperative systemic therapies for non-small-cell lung cancer: Recent advances and future perspectives
    Lampridis, Savvas
    Scarci, Marco
    FRONTIERS IN SURGERY, 2023, 9
  • [49] Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
    Koulouris, Andreas
    Tsagkaris, Christos
    Corriero, Anna Chiara
    Metro, Giulio
    Mountzios, Giannis
    CANCERS, 2022, 14 (14)
  • [50] Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer
    Baglivo, Sara
    Ludovini, Vienna
    Sidoni, Angelo
    Metro, Giulio
    Ricciuti, Biagio
    Siggillino, Annamaria
    Rebonato, Alberto
    Messina, Salvatore
    Crino, Lucio
    Chiari, Rita
    MAYO CLINIC PROCEEDINGS, 2017, 92 (08) : 1304 - 1311
12345